Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31221629 | 0.94 | TSHR (0.45) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 | |
| SCHEMBL13610195 | 0.94 | TSHR (0.45) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 | |
| SCHEMBL24489216 | 0.94 | TSHR (0.45) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 | |
| SCHEMBL1949239 | 0.90 | SLC6A1 (0.50) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 | |
| SCHEMBL30376402 | 0.90 | GNAI3 (0.42) | TSHRATMMAPTEPHX2ALDH1A1 | |
| SCHEMBL3002273 | 0.90 | GNAI3 (0.42) | TSHRATMMAPTEPHX2ALDH1A1 | |
| SCHEMBL27515956 | 0.88 | SLC6A1 (0.42) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 | |
| SCHEMBL11848695 | 0.84 | GNAI3 (0.47) | TSHRSMN1; SMN2EPHX2 | |
| SCHEMBL13610202 | 0.84 | GNAI3 (0.47) | TSHRSMN1; SMN2EPHX2 | |
| SCHEMBL132089 | 0.83 | SLC6A1 (0.53) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101209990-B | Resolution method for 3-piperidine formic acid ester | Jiangsu tianzhi chemical co ltd | 2010-11-10 | — | — | CN | claimed |
| CN-101209990-A | Resolution method for 3-piperidine formic acid ester | JIANGSU TIANZHI CHEMICAL CO LT (CN) | 2008-07-02 | — | — | CN | claimed |
| US-20250270189-A1 | Ester Substituted Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20240116895-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2024-04-11 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3937934-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113924094-A | Ester-substituted ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20210070734-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-10927096-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200290991-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2020185915-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-1993025205-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-23 | — | — | WO | disclosed |
| US-5179103-A | Diuretics, hypotensive agents | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5102878-A | Treating psychological, bone, cardiovascular, blood disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5102869-A | Urogenital disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5087629-A | Diuretics, hypotensive agents; cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-4994453-A | Treating asthma, diabetes, obesity, immunosuppression | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116895-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, TRPV2 | SLC6A1 262/4885TSHR 3755/4885SLC6A11 394/4885 |
| US-20210070734-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, TRPV2 | SLC6A1 262/4885TSHR 3755/4885SLC6A11 394/4885 |
| US-10927096-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | SLC6A1 262/4885TSHR 3755/4885SLC6A11 394/4885 |
| US-20200290991-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, TRPV2 | SLC6A1 262/4885TSHR 3755/4885SLC6A11 394/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | SLC6A1 262/4885TSHR 3755/4885SLC6A11 394/4885 |
| US-20250270189-A1 | Ester Substituted Ion Channel Blockers and Methods for Use | TRPV1, TRPA1, TRPV2 | SLC6A1 262/4885TSHR 3755/4885SLC6A11 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.